Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Response Rate
Epistemonikos ID: 02b61bff10d1033df8b041bcb961b95c4b3f086d
First added on: May 11, 2024